Posts in Category: Immunobody

Scancell licenses key ImmunoBody® patents from Merck Serono

Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody® platform, is pleased to announce it has signed a licensing agreement with Merck KGaA, Darmstadt, Germany, acting for its division Merck Serono, for two key patents required for the further development and commercialisation of protein ImmunoBody® vaccines. Under the agreement, Scancell has non-exclusive worldwide rights to use the two patents to further develop and commercialise ImmunoBody® vaccines in all therapeutic areas in both humans and animals.

In addition, Scancell has granted Merck Serono an option to negotiate an exclusive license under Scancell's ImmunoBody® platform technology for up to five Merck Serono targets.

Scancell's ImmunoBody® is a breakthrough patent-protected platform technology that aims to overcome the current limitations of cancer vaccines by generating the high-avidity T-cells that kill cancer cells.

By re-engineering the vector, the Immunobody® platform technology can be adapted to provide the basis for treating any tumour type and may also be of utility in the development of vaccines against chronic infectious diseases including hepatitis and HIV.

Scancell's first cancer vaccine SCIB1 is being developed to treat melanoma, with clinical trials commencing in 2010.

David Evans, chairman of Scancell, commented:

"We are delighted to have forged this association with Merck Serono. The agreement will add further strength to Scancell's IP position, as it continues to progress its development of therapeutic vaccines based on the Immunobody® platform."

For Further Information:

Professor Lindy Durrant   Scancell Holdings Plc + 44 207 245 1100  
Adam Reynolds/Vikki Krause    Hansard Group   + 44 7515 922906   
Ross Andrews      Zeus Capital  + 44 (0)161 831 1512



 

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and will enter clinical trials in early 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Scancell Receives GBP250,000 emda Grant

Scancell Holdings plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody(tm) platform, is pleased to announce that it has been awarded a £250,000 Grant for Research and Development (`GRD') by the East Midlands Development Agency (`emda'). The GRD will be used towards the costs of progressing Scancell's SCIB1 ImmunoBody DNA vaccine as it commences Good Manufacturing Practice (`GMP') production in 1Q2009 and applies for Clinical Trial Authorisation (`CTA') to commence clinical trials of SCIB1 in the UK in 1Q2010.

Scancell is developing SCIB1, a DNA vaccine for the potential treatment of late-stage melanoma cancer patients. There are 8000 new cases of melanoma every year in the UK with 1800 deaths per year. Early stage melanoma is often cured by surgery but advanced disease has a very poor prognosis with late stage (stage IV) disease having a median survival of approximately 6 months. SCIB1 was developed using Scancell's ImmunoBody(tm) technology and is engineered to express the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In animal models, SCIB1 prevented the development of lung metastases and significantly inhibited the growth of established tumours.

The emda grant will be used to help fund the preparatory programme for phaseI/ IIa clinical trials that are anticipated to commence in 2010. The programme includes: optimisation of the ImmunoBody(tm); GMP process manufacture, formulation, stability and scale-up; pre-clinical efficacy and safety testing, and; toxicological assessment. The data derived from these studies will be utilised by Scancell in order to obtain CTA to allow the first clinical trial of SCIB1 in melanoma patients.

emda is one of nine Regional Development Agencies in England, set up in 1999 to bring a regional focus to economic development. Its primary goal is to increase the economic growth of the region while reducing disparities between the East Midlands and other English regions. The key role of emda is to be the strategic driver of sustainable economic development, working in partnership with public, private and voluntary organisations to deliver the goals of the Regional Economic Strategy.

David Evans, Chairman of Scancell, commented:

"We are delighted to have received a £250,000 grant from emda, the proceeds of which will be used to further progress SCIB1 and to further explore the manifold opportunities we expect that our ImmunoBody(tm) platform will present for the treatment of cancer, and other serious diseases. We are also pleased to be recognised by emda as a contributor to the economic growth prospects of the East Midlands region and appreciate the support that emda is providing towards building our business and the successful development of our innovative technology."

John O'Reilly, Business Support Director at emda, commented:

"Scancell is just the kind of innovative company that we are looking to support through the Grant for Research and Development. The grant will help it to develop a revolutionary new treatment which will not only help thousands of people affected by cancer, but which will also enable the business to develop and grow, creating new jobs for the region."

The Directors of the issuer accept responsibility for this announcement.

GMP Manufacture Deal With Cobra

Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody(tm) platform, is pleased to announce that it has signed a deal with Cobra Biomanufacturing Plc (`Cobra Biomanufacturing') for Good Manufacturing Practice (`GMP') manufacture of its SCIB1 DNA vaccine. Scancell plan to commence clinical trials of SCIB1 in the UK in 1Q2010.

Scancell is developing SCIB1, a DNA vaccine for the potential treatment of late-stage melanoma cancer patients. There are 8000 new cases of melanoma every year in the UK with 1800 deaths per year. Early stage melanoma is often cured by surgery but advanced disease has a very poor prognosis with late stage (stage IV) disease having a median survival of approximately 6 months. SCIB1 was developed using Scancell's ImmunoBody(tm) technology and is engineered to express the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In animal models, SCIB1 prevented the development of lung metastases and significantly inhibited the growth of established tumours.

Cobra Biomanufacturing is an AIM-listed contract manufacturer of biopharmaceuticals that is compliant with cGMP standards worldwide.

David Evans, chairman of Scancell, commented:

"We are delighted to sign a deal with Cobra Biomanufacturing to manufacture our SCIB1 DNA vaccine. That we are commencing GMP manufacture of SCIB1 on schedule is testament to the progress the Company continues to achieve."

Simon Saxby, Chief Executive of Cobra Biomanufacturing said:

"We are very pleased to be have been selected by Scancell as a result of Cobra's abilities and reputation as a leading cGMP compliant manufacturer of DNA. This agreement also underscores Cobra's long term commitment to the manufacture of therapeutic vaccines."

The Directors of the issuer accept responsibility for this announcement.  

Interim Results for the six month period to 31 October 2008

The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’),
the developer of cancer vaccines based on its patented ImmunoBody™ platform, are pleased
to announce the interim results for Scancell for the six month period ended 31st October 2008
(‘the period’).

Highlights:

  • Admitted to Plus markets on 24 September 2008 and raised £1.559,502 on 24th September 2008
  • Issue of equity raised £43,999.8 on the 19th of December 2008
  • Following the placing of shares in September, the Company has £2,220,479 cash reserves
  • Continued make good progress towards its goal of starting Phase 1 clinical trials with SCIB1 in 2010
  • Agreement to license key components of SCIB1 from National Institute for Health (‘NIH’) in the final phase of negotiation
  • Negotiations to secure development and commercial rights to an injection device to deliver SCIB1 to patients progressing wel
  • Experienced Development Advisor appointed for SCIB1
  • Presented at the Genesis 2008 Oncology Showcase

David Evans, Non-Executive Chairman of Scancell, commented:

“I am delighted to report a very successful first six months as a public company. In 2008, we raised £1.6m in conjunction with being admitted to Plus markets. The funds raised will provide the ability to further develop Scancell’s core technology; the ImmunoBodyTM platform and to achieve its aim of starting Phase 1 clinical trials of SCIB1 in 2010.”

For further information contact:

Company:
Scancell Holdings Plc  -  Professor Lindy Durrant/Dr Richard Goodfellow  -  Tel: 020 7245 1100

Corporate Advisers:
St Helen's Capital Plc  -  Duncan Vasey/Barry Hocken  -  Tel: 020 7628 5582

Financial PR:
Hansard Group  -  Adam Reynolds/Vicky Krause  -  Tel: 020 7245 1100

View the full results

Audited Final Results for the Year Ended 30 April 2008

The Directors of Scancell Holdings Plc are pleased to announce the audited results for Scancell Limited for the year ended 30 April 2008.

Chairman's Statement

In the last financial year we have consolidated our position in relation to the science and the finances of the Company.

In November, I was elected Non-Executive Chairman and brought my considerable experience in listed companies to the board. A decision was made at the beginning of 2008 to list the Company on the PLUS Market (www.PLUSmarketsgroup.com) and successfully achieved on the 24th of September 2008.This has attracted new finance to progress our lead product SCIB1 into the clinic and continue the development of the ImmunoBody platform. A decision was made by the directors that they are not paying a dividend for the period.

We look forward to updating shareholders with developments over the coming months.

For the full report click here

Scancell Raises £1.0 Million In Rights Issue

Oxford, UK, 15 June 2005 - Scancell Limited announces the completion of its Rights Issue funding of £1.0m. The round was well supported by Scancell’s existing shareholders who include, Bioscience VCT, Oxford Capital Partners and the Oxford Technology VCTs.

Scancell will use the funds to advance its development programmes as it advances towards the clinic. Based in Biocity, Nottingham, UK, Scancell is one of the leading drug discovery companies focused on cancer therapeutics through the development of its antibody technology. Scancell was founded in 1997 as a spin out of the University of Nottingham by Professor Lindy Durrant.

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The Company has four therapeutic antibodies in development and a pipeline of improved cancer vaccines based upon its proprietary ImmunoBody® technology. Scancell has already secured major technology-validating collaborations with significant players in the sector including Celltech, Genmab and ISU.

Mike Capaldi, CEO of Scancell, said: “We are pleased to have received strong support from our shareholders. Despite the challenging environment for biotech funding, Scancell has successfully closed this round and is in discussions with a number of commercial partners.”

David Mott, Partner at Oxford Capital Partners, said: “Scancell have made strong scientific progress over the past 18 months and we are confident that the technology will deliver. The new funds will enable Scancell to reach several critical value milestones.”

Scancell Secures Exclusive Worldwide Licence Agreement

Nottingham, UK – 25th May 2004 – Scancell Ltd, the Nottingham, UK based cancer therapeutics company, has announced that it has secured an agreement with Cancer Research Technology Limited (CRT) under which Scancell has been granted an exclusive worldwide licence to develop and commercialise two cancer vaccines against Tie-2 and CD55 protein targets for the treatment of solid tumours.

Tie-2 and CD55 offer highly promising approaches to the development of novel vaccines using Scancell's ImmunoBody™ technology. Tie-2 is over-expressed on tumour vasculature. Therapeutic vaccines targeting blood vessels can cause vascular collapse and starvation of large tumour areas. CD55 is over-expressed by tumours to protect them from immune attack. A therapeutic vaccine targeting CD55 may therefore destroy tumour cells over-expressing CD55 leaving any remaining cells susceptible to immune clearance through endogenous complement lysis. A combination of both vaccines may lead to dramatic tumour regression by harnessing the body's immune system to 'reject' the tumour.

Commenting on the agreement, Professor Lindy Durrant, CSO of Scancell, said: "We are very pleased that CRT has selected Scancell to develop and commercialise these extremely promising products. This agreement offers Scancell the opportunity to develop two new ImmunoBody™ vaccines for the treatment of solid tumours. The collaboration with CRT is a further example of how we intend to accelerate the development of the ImmunoBody™ programme through partnerships over the next few years."

Dr. Keith Blundy, Chief Operating Officer at CRT, said: "Scancell is well positioned to develop the CD55 and Tie-2 vaccines and we anticipate that this deal will enable cancer patients to benefit from this exciting technology in the future."

Scancell's ImmunoBody® approach involves engineering a human antibody to express epitopes from tumour antigens over-expressed by commercially important solid tumours - in this case Tie-2 and CD55. ImmunoBody™ vaccines efficiently target the dendritic cells in vivo to stimulate effective immunity. They offer the potential to develop more effective vaccines against both cancer and infectious diseases.

Scancell Raises £1.3 Million ($2.34M; €2M) in New Funding Round

Nottingham, UK – 27th April 2004 – Scancell Ltd, the Nottingham, UK based cancer therapeutics company, announced at its annual general meeting (AGM) today the successful completion of a further round of private equity funding totalling ~£1.3 million. Bioscience VCT, and Oxford Technology 3 VCT, an existing investor, acted as co-lead investors for the round. Other new investors in this round included Oxford Capital Partners and Cherwell Capital. Several of Scancell’s existing investors also made additional investments in the company.

The new funding will allow Scancell to accelerate the development of its leading products and to move to dedicated laboratories at the new BioCity Healthcare and Bioscience Innovation Centre in Nottingham, UK.

Commenting on the funding Dr Mike Capaldi, Scancell’s new CEO said:

“Scancell is very pleased to have succeeded in securing this investment in the current difficult market conditions. The company has already demonstrated its ability to develop new products and close commercial deals. The new investment will allow the company to bring its products closer to the clinic and to further develop its ImmunoBody® programme. We are also very excited about the move to BioCity, which will significantly help our growth plans.”

Dr Paul Nicholson, the Chairman of BioScience VCT, said:

“We are pleased to have made an investment in Scancell. The company has built a strong team to lead the development of its antibodies and its platform technologies and we look forward to supporting the company’s progress.”

Lucius Cary, Director of Oxford Technology 3 VCT, and the Managing Director of Seed Capital Ltd, the Investment Adviser to the Oxford Technology 3 VCT added:

“We are very pleased to have invested further in Scancell and continue to support the company and the research of its founder, Professor Lindy Durrant. This is a company that has developed a diverse pipeline of anti-cancer targets and platform technologies and assembled an outstanding team to deliver these to the clinic.”

Scancell Appoints Dr Michael Capaldi as CEO

Nottingham, UK – 21st April 2004 – Scancell Ltd, the pioneering Nottingham-based therapeutics company that is harnessing the power of the immune system to fight cancer, has announced the appointment of Dr Michael Capaldi as Chief Executive Officer. Dr Capaldi brings to Scancell extensive commercial and management experience in the pharmaceutical and life sciences industries, together with a strong scientific background.

Commenting on his new position, Dr Capaldi said:

“Scancell is at an exciting stage of development and I look forward to contributing to the future success of the Company. I am convinced that Scancell can make a major contribution towards developing new cancer therapies that harness the power of the immune system.”

Dr Capaldi was previously CEO of Synaptica Ltd where he served from 2000. He has a broad working knowledge of the biopharmaceutical industry with a strong commercial bias, combined with a solid understanding of pharmaceutical discovery and development. He has first hand experience of raising capital from private and public markets to fund early stage biotechnology companies including an IPO of Core Group as a full listing on the London Stock Exchange (LSE) in 1997. He has over 20 years experience in the pharmaceutical and life sciences industry within the UK, Europe and the USA, including over 17 years commercial and general management experience gained with SmithKline Beecham plc, Amersham plc, Core Group plc, Oxford Asymmetry plc and Synaptica Ltd. Prior to this he gained five years multidisciplinary research experience in academic and applied pharmaceutical research and management with Ciba-Geigy.

Michael holds a PhD in Medical Biophysics from the University of Manchester, and has experience of both academic and applied pharmaceutical research. Welcoming Dr Capaldi to the Company, Chairman Nigel Evans said: “Michael brings significant management, commercial and fund raising experience to Scancell, which will be invaluable as the Company commercialises its therapeutic antibodies and it’s ImmunoBody® technology. Monoclonal antibody technology promises considerable hope for the treatment and prevention of cancer.”

Scancell, Onyvax and CRT Announce Agreement to Facilitate the Development of "ImmunoBody"

Nottingham and London, UK – 12th December 2003 – Scancell Ltd., Onyvax Limited and Cancer Research Technology Limited (CRT), today announced an agreement enabling Scancell to develop and commercialise its proprietary ImmunoBody cancer vaccine technology. Under the terms of the agreement Onyvax, one of the world's leading cancer vaccine companies, will also have a non-exclusive licence to develop the technology.

The ImmunoBody Approach

Cancer vaccines represent a highly attractive approach for cancer therapy as, in contrast to current treatments such as chemotherapy and radiotherapy, small non-toxic doses of a vaccine may be administered to a patient to stimulate an immune response. It is generally accepted that to be effective against cancer, a vaccine needs to target dendritic cells to stimulate both parts of the cellular immune system, the helper cell system (known as the CD4-mediated response) which stimulates inflammation at the tumour site, and the cytotoxic T-lymphocyte or CTL response (known as the CD8-mediated response) in which cells of the immune system are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive.

Scancell's ImmunoBody approach involves engineering a human antibody to express helper cell and CTL epitopes from tumour antigens over-expressed by commercially important solid tumours. These ImmunoBodies efficiently target dendritic cells in vivo via the CD64 receptor to stimulate effective immunity. They offer the potential to develop more effective vaccines against both cancer and infectious diseases.

Commenting on the agreement, Professor Lindy Durrant, CEO of Scancell, said: "We are very pleased to have reached agreement with CRT and Onyvax on the ImmunoBody programme. This platform offers Scancell the opportunity to develop new cancer vaccines on its own behalf and in partnership with others. The collaboration with Onyvax is the first exciting example of how we intend to accelerate the development of the ImmunoBody programme through partnerships over the next few years."

Dr Anthony Walker, CEO of Onyvax, commented: "Scancell's ImmunoBody technology is potentially a breakthrough in cancer vaccine design, offering the opportunity to develop more effective vaccines against this disease."

Dr Keith Blundy, Director of Business Management at CRT, said: "We are very pleased that Scancell and Onyvax will be undertaking further development of the ImmunoBody technology and hope that the programme will lead to new therapeutic options for cancer patients."